ChromoTek's Chromobody® Technology is a patented, universal live cell imaging technology for high content analysis. Chromobodies are single domain antibodies that have been genetically fused to fluorescent proteins to serve as functional nanoprobes in living cells. The Chromobody® technology allows for the first time to trace endogenous intracellular antigens and to visualize dynamic changes of these targets within living cells. Currently available Chromobodies trace important cellular processes like cell cycle, apoptosis, DNA damage and repair or allow cytoskeletal analysis. The Cell Cycle Chromobody® cell line licensed by Bayer traces the complete cell cycle in real time in live cells in a non-invasive manner while providing full flexibility to multiplex with other procedures.
Dr. Kourosh Zolghadr, Head of R&D at ChromoTek comments: "We are pleased to offer our customers efficient tools for achieving more detailed and physiologically relevant information on the effects of drug candidates on cell cycle progression."
About ChromoTek
ChromoTek products set new benchmarks for cellular research. Established in 2008 as a spin-off from Munich’s Ludwig Maximilian University and located in Martinsried, Germany’s leading biotech cluster, ChromoTek develops and markets Chromobody® based live cell assays for drug screening and target validation. Other products include immunological and bioimaging reagents such as the GFP-Trap® for the rapid pull-down of GFP fusion proteins, GFP and RFP Booster to amplify fluorescence signals of GFP or RFP fusion proteins. ChromoTek’s newly developed fluorescence based protein protein interaction assay called Fluorescent-2-Hybrid (F2H) is available as a development service. More than 2.800 customers from all over the world trust in ChromoTek products.
Contact:
ChromoTek GmbH
Am Klopferspitz 19
82152 Martinsried
ph: +49 89 78 79 73 03
www.chromotek.com
